Tandem Diabetes Care (Nasdaq:TNDM) announced today that it made a new, limited-time offer for its Tandem Choice technology access program.
San Diego-based Tandem Diabetes Care’s program provides new and renewing, eligible users of its insulin pump a pathway to its new offerings. Users of the t:slim X2 insulin pump in the U.S. can use the program to move toward owning a Tandem Mobi system for $199.
The FDA cleared the Mobi automated insulin delivery (AID) system earlier this month. Tandem Diabetes Care expects to begin a limited launch later this year, with general availability slated for early 2024.
Mobi — fully controllable from a mobile app — is the world’s smallest durable AID system. It features a 200-unit insulin cartridge and an on-pump button to provide an alternative to phone control for insulin boluses. Mobi comes in at less than half the size of the existing Tandem pump system, the t:slim X2 pump.
It can fit in a coin pocket, clip to clothing or go on the body with an adhesive sleeve.
Who is eligible for this program?
Tandem Diabetes Care said that it plans to make the program available at the discounted price for customers who purchased a t:slim X2 between July 1 and Dec. 31 of this year. Customers who purchased the pump before July 1 and have 12 months or more remaining on an existing warranty may participate in the program for the originally offered price of $999.
According to the company, customers don’t need to take action or elect to participate at this time. They can choose to participate any time before Dec. 31, 2024. If so, they can make a one-time switch from t:slim X2 to Tandem Mobi.
“Tandem Choice provides our customers time to decide which of our pump platforms best meets their needs and preferences, without having to delay experiencing the benefits of our Control-IQ technology,” said John Sheridan, president and CEO. “Our #1 rated t:slim X2, designed for people who want the convenience of an integrated touchscreen device, and our new Tandem Mobi, which offers smartphone control and new wearability options, provides people living with diabetes the power of choice in customizing an automated insulin delivery system to meet their individual needs.”